---
figid: PMC9623415__fendo-13-1010092-g001
pmcid: PMC9623415
image_filename: fendo-13-1010092-g001.jpg
figure_link: /pmc/articles/PMC9623415/figure/f1/
number: Figure 1
figure_title: ''
caption: 'Pathways involved in the induced trastuzumab resistance of T15 (log2 FC
  normalized to SKBR3 signals). Similarly expressed protein: light grey; antibody
  not available/poor performance: no fill; overexpressed total protein ≥ 1.5-fold
  (log2 FC ≥ 0.58): light orange; ≥ 2-fold: *; over-represented phosphosite ≥ 1.5-fold:
  orange; ≥ 2-fold: *; predicted active protein: dark red outline.'
article_title: PKC-mediated phosphorylation and activation of the MEK/ERK pathway
  as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.
citation: Jeanesse Scerri, et al. Front Endocrinol (Lausanne). 2022;13:1010092.
year: '2022'

doi: 10.3389/fendo.2022.1010092
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.

keywords:
- acquired resistance
- breast cancer
- phospho-profile
- PKC/MEK/ERK
- signalosome
- HER2 positive
- patient stratification

---
